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Abstract
Amyloidosis refers to a heterogeneous group of diseases in which a soluble precursor,
misfolded protein, and subsequently aggregates into highly structured protein fibrils
with a cross-β-pleated structure. Of these diseases, amyloid A (AA) amyloidosis is a
complication of long-standing inflammatory diseases such as rheumatoid arthritis (RA).
Treatment of this amyloidosis with RA aims to stop serum AA protein production.
Immunosuppressants have reportedly been useful for both RA inflammation and AA
amyloidosis. Also, biologics are effective for these specific pathological processes by
targeting  key  players  in  each  inflammation.  In  addition  to  the  above-mentioned
medications, agents both inhibiting AA fibrillogenesis and destabilizing AA fibrils have
recently been employed. Phagocytes play important roles in the regression of AA fibrils.
Renal involvement is the most common complication in AA amyloidosis. Peritoneal
dialysis, hemodialysis, and even renal transplantation are available for patients with
end-stage  renal  disease  and  AA  amyloidosis.  This  chapter  thus  discusses  current
developments in the treatment of AA amyloidosis secondary to RA.
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1. Introduction
Amyloidosis is a rare disorder in which extracellular amyloid fibrils are deposited in vari‐
ous tissues. Those fibrils derive from the misfolding of precursor proteins, the result being
multiple organs dysfunction. Systemic amyloidosis is thus characterized by failure of all sorts
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of organs and the presence of amyloid precursor protein in the serum. Reactive amyloid A
(AA) amyloidosis is one of the most severe complications of a number of chronic disorders,
especially rheumatoid arthritis (RA); most patients with this amyloidosis have an underly‐
ing rheumatic disease. AA amyloidosis, an extra-articular complication of RA, is a serious
disorder, possibly life-threatening, that is caused by deposition in multiple organs of AA
amyloid fibrils which originate from the circulatory acute-phase reactant, serum amyloid A
protein (SAA) [1–4].
Both treatment and understanding of the roles of cytokines in RA have resulted in consider‐
able progress. Remarkable advances, which not only provide insight into the pathophysiolo‐
gy of the disease but also aid discovery of new therapies to fight the deadly disease, have
recently been made [5, 6]. For example, the introduction of biological therapies targeting
specific inflammatory mediators revolutionized RA treatment. Focusing on essential compo‐
nents of the immune system allows effective suppression of the pathological inflammatory
cascade that produces RA symptoms and the resulting joint destruction [7–10]. Several new
biologics may permit AA amyloidosis secondary to RA to become a treatable, even manage‐
able, disease. Furthermore, that the allele SAA1.3 is not only a univariate predictor of surviv‐
al but also a risk factor for the association of AA amyloidosis with RA in Japanese patients is
very interesting [11].
Patients with RA, who have a less-than-optimal response to or cannot tolerate conventional
synthetic disease-modifying antirheumatic drugs (csDMARDs) [12], such as methotrexate
(MTX) [13, 14], are often prescribed biological DMARDs (bDMARDs). Treatment of AA
amyloidosis caused by RA seeks to stop SAA production [15]. This approach to AA amyloi‐
dosis treatment is the most common and best-studied therapy; it interferes with synthesis of
the precursor protein, with the goal of preventing continued amyloid fibril formation.
Similarly, cytotoxic immunosuppressants, such as chlorambucil and cyclophosphamide
(CYC), have reportedly been useful for both RA inflammation and AA amyloidosis [16–20].
An alternative approach to therapy involves developing drugs to inhibit amyloid fibrillogen‐
esis. One technique targets AA amyloid deposits directly, by destabilizing AA amyloid fibrils
so that they cannot maintain their structural configuration. Treatment with the drug (R)-1-[6-
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), a
novel hexanoyl bis(D-proline), effectively removes the serum amyloid P component (SAP)
from plasma but leaves some SAP in amyloid deposits that can then be specific targets of
therapeutic IgG anti-SAP antibodies [21]. Also, eprodisate, which binds to glycosaminogly‐
can-binding sites on AA amyloid fibrils and in theory would destabilize them in tissues, may
thereby cause regression of AA amyloidosis [22]. Although the mechanisms by which amyloid
deposits are cleared are not well known, they supposedly involve breakdown of amyloid fibrils
and associated molecules by macrophages and/or parenchymal cells [23, 24].
This chapter aims to review the advances in the treatment of AA amyloidosis secondary to RA
and to describe the latest therapeutic developments based on our reports and literature
reviews.
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2. SAA1.3 genotype and SAA concentration as predictive and prognostic
factors of AA amyloidosis outcome
The frequency of SAA1 gene polymorphism and that of SAA1 alleles differ among races and
regions worldwide. Three main SAA1 alleles—SAA1.1, SAA1.3, and SAA1.5—are defined by
two single-nucleotide polymorphisms (SNPs) in exon 3, which result in two amino acid
differences at positions 52 and 57, respectively, [25]. In Japanese people, the three alleles occur
approximately at the same frequency. The association between AA amyloidosis and the SAA1
genotype was first observed in Japanese patients with RA, in whom SAA1.3 allele homo‐
zygosity proved to be a risk factor [26]. The SAA1.3/1.3 genotype in Japanese patients with RA
was related to a shorter latency before the onset of AA amyloidosis and more severe AA
amyloidosis-related symptoms [27, 28]. In addition, it was a univariate predictor of survival
(Figure 1). Thus, the SAA1.3 allele was a risk factor for AA amyloidosis, was associated with
clinical severity of the disease, and poor prognosis [11]. In Caucasians, AA amyloidosis was
often found in SAA1.1 homozygous individuals, and the SAA1.1 allele was believed to be a
risk factor for AA amyloidosis [29]. As for SNPs of the SAA1 gene promoter region, –13T was
found to be a high-risk factor for AA amyloidosis in Japanese patients with RA, and –13T/T
and –13T/C were more closely correlated with AA amyloidosis compared with –13C/C [30].
SAA1 gene polymorphism affects both SAA transcriptional activity in hepatocytes and blood
SAA levels, so differences in enzymatic SAA1 proteolysis have demonstrated a close associa‐
tion between SAA1 gene polymorphism and the onset of AA amyloidosis [31]. However, the
mechanism by which SAA1 gene polymorphism is associated with of AA amyloidosis onset
and the reason for ethnic differences in disease-susceptible SNPs are still unknown.
Figure 1. Kaplan-Meier survival curves for RA patients with and without SAA1.3/1.3. Statistical analysis of a large
number of RA patients with AA amyloidosis who carried the SAA1.3 allele revealed that the risk for association with
AA amyloidosis was about eight times higher for SAA1.3 homozygotes than for the control group and that homozy‐
gotes could develop AA amyloidosis very early after RA onset. Quoted from Nakamura et al. Rheumatology (Oxford)
2006; 45: 43–49.
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Figure 2. Kaplan-Meier survival curves for patients with systemic AA amyloidosis stratified according to whether the
SAA concentration was above or below 10 μg/ml. During follow-up, the proportion of patients with AA amyloidosis
who remained alive at 10 years was 90% in the group with median SAA values below 10 μg/ml and 40% in the group
with SAA values above that value. Quoted and modified from Gillmore et al. Lancet 2011; 358: 24–29.
The current primary objective of therapy for all forms of amyloidosis was the reduction of the
precursor protein supply [32]. In AA amyloidosis, long-term suppression of SAA levels is
critical for patient and disease outcomes and for AA amyloidosis in patients with RA. The
degree to which SAA concentration increased during follow-up was a strong predictor of
outcome [33]. Sustained complete suppression of RA disease activity with the normalization
of SAA levels should be the treatment aims in patients with AA amyloidosis, and monitor‐
ing the SAA levels is a vital part of patient management (Figure 2) [34].
Figure 3. Biological versatility of SAA. SAA has important roles in high-grade and low-grade inflammation. Similar to
cytokines, it utilizes autocrine, endocrine, and paracrine mechanisms. SAA, as a precursor protein of AA amyloidosis,
induces this amyloidosis. Using different modes of action, SAA also affects metabolic syndrome. These humoral and
cellular inflammatory events interact, with SAA as an essential factor. RAGE: receptor for advanced glycation end
products; FPRL1: formyl peptide receptor-like 1; TLR2, 4: toll-like receptors 2 and 4; CLA-1: CD36, and LIMPII analo‐
gous-1, a human ortholog of the scavenger receptor class B type I (SR-BI); AGEs: advanced glycation end products.
Quoted from Nakamura T. Clin Exp Rheumatol 2011; 29: 850–857.
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SAA plays important roles in both high-grade and low-grade inflammation (Figure 3) [35].
Similar to cytokines, SAA operates by means of autocrine, endocrine, and paracrine mecha‐
nisms. SAA is a precursor protein of AA amyloid fibrils, and it induces AA amyloidosis. SAA
also functions in metabolic syndrome by means of different modes of action. As a critical factor
in the inflammatory interactions, SAA acts mutually among humoral and cellular events
within inflammation.
3. Treatment with conventional synthetic DMARDs for AA amyloidosis
secondary to RA
Treatment of patients with RA has focused on using immunosuppressants as conventional
synthetic DMARDs (csDMARDs). Although case reports and studies of small series of patients
showed that immunosuppressants can reverse nephrotic syndrome [36] and can even lead to
complete resolution of proteinuria [37, 38], as Table 1 shows, management of AA amyloido‐
sis has focused on the RA process causing the inflammation as the underlying disease. We
cannot, therefore, determine a clear difference in the effectiveness of therapies for RA and AA
amyloidosis.
No. of cases Diagnosis Treatment References
1 RA CYC Acta Med Scand 1979; 205: 651
11 RA CYC/podophyllotoxin/
chlorambucil/ azathioprine
Clin Rheumatol 1987; 6: 27
9 RA Chlorambucil/CYC Ann Rheum Dis 1987; 46: 757
1 RA Chlorambucil S Afr Med J 1988; 73: 55
4 JIA Chlorambucil Pediatr Nephrol 1990; 4: 463
3 RA/JIA CYC/methotrexate Medicine (Baltimore) 1991; 70: 246
12 RA/JIA Chlorambucil/CYC J Rheumatol 1993; 20: 2051
1 RA CYC Clin Nephrol 1994; 42: 30
1 RA Azathioprine Arthritis Rheum 1995; 38: 1851
1 RA CYC Mod Rheumatol 2000; 10: 160
4 RA CYC Arthritis Rheum 2001; 44: 66
15 RA CYC Rheumatology (Oxford) 2001; 40: 821
15 RA CYC Clin Rheumatol 2003; 22: 371
AA: amyloid A; RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; CYC: cyclophosphamide.
Table 1. Reported cases in the treatment for AA amyloidosis secondary to RA/JIA with immunosuppressants.
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The efficacy of corticosteroid treatment with regard to AA amyloidosis secondary to RA is still
controversial [39]. Corticosteroids can reduce the magnitude of acute phase reactions includ‐
ing synthesis of C-reactive protein (CRP) and SAA. In cultures of human hepatocyte, cortico‐
steroids stimulated SAA production but not CRP production. Although corticosteroids
reduced SAA and CRP levels in longitudinal studies of patients with RA, the effect was
somewhat greater for CRP than for SAA [40]. Growing evidence suggests that SAA is sensitive
to change, achieves much higher levels than CRP, declines rapidly, and may therefore
accurately reflect disease activity. The advantages of SAA as a biomarker of disease activity
include the rapid production and exceptionally wide dynamic range of the inflammatory
response. During acute inflammation, serum SAA levels may rise up to 1000-fold and the
biologic half-life of SAA levels are significantly shorter than that of CRP [41]. Monitoring SAA
instead of CRP levels would thus be advisable, especially if corticosteroids are used. Treating
patients with AA amyloidosis secondary to RA using cytotoxic drugs either alone or togeth‐
er with prednisolone, which is a synthetic glucocorticoid and a cortisol derivative, seems
reasonable [42]. Because the effect of immunosuppressants may require weeks or months to
be obvious, giving steroids in addition to immunosuppressants is recommended to ensure an
immediate reduction in the acute phase response and, in particular, SAA synthesis [43].
Figure 4. Differences between CYC and methotrexate (MTX) treatments in RA patients with AA amyloidosis. The de‐
ducted value (in the figure) was determined by subtracting the starting CRP and serum creatinine values from the
corresponding ending values in each treatment. Quoted from Nakamura et al. Rheumatology (Oxford) 2006; 45: 43–49.
Although no evidence is available that csDMARDs have a particular effect on amyloidogen‐
esis and AA amyloidosis in RA, reports provided encouraging description of the beneficial
results of alkylating agents in clinical trials in RA patients with AA amyloidosis [44–46]. Using
immunosuppressive agents may improve prognosis, and CYC has proved to be superior
compared with methotrexate (MTX) for the treatment of RA patients with AA amyloidosis
(Figure 4) [11]. Because between before and during CYC treatment, the values of Lansbury
index, which implies a statistical approach to indices of disease activity, have lowered more;
CYC may be more effective mainly in patients with SAA1.3 homozygosity than in patients
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with SAA1.3 heterozygosity, which suggests that SAA1.3 homozygosity is a CYC treatment-
susceptible factor (Figure 5) [20].
Figure 5. Changes in Lansbury index after CYC or prednisolone treatment in RA patients with AA amyloidosis with
SAA1.3 heterozygosity or homozygosity. In SAA1.3 homozygous patients, a statistically significant difference occurred
between before and during, whereas SAA1.3 heterozygous patients showed no such significant difference. Quoted
from Nakamura et al. Clin Rheumatol 2003; 22: 371–375.
During signal transduction, interleukin-6 (IL-6) binds to the membrane-bound IL-6 receptor
gp80 [47], and after which the IL-6-gp80 dimer interacts with gp130. Formation of gp130-
containing complexes activates Janus kinases, which stimulates signal transducers and
activators of transcription (STATs) [48–50]. Some evidence suggests that STAT3 is the critical
transcription factor that is responsible for IL-6 activation of SAA gene transcription [51]. The
function of Janus kinase inhibition in the IL-6-signaling pathway will thus be one target of RA
treatment. Suppressing IL-6-mediated pro-inflammatory signaling pathways using Janus
kinase inhibitors may be a novel anti-inflammatory therapeutic strategy for RA and AA
amyloidosis.
Another agent, tacrolimus, may inhibit T-cell function in the pathogenesis of AA amyloido‐
sis. In experimental murine models of AA amyloidosis, blocking the function of T lympho‐
cytes with the calcineurin inhibitor tacrolimus showed that it inhibited deposition of AA
amyloid fibril in a dose-dependent manner. Also, the location of CD4+ T lymphocytes in the
spleen was identical to that of AA amyloid fibril deposits, which suggests that T lympho‐
cytes have a role in the pathogenesis of AA amyloidosis [52].
4. Treatment with biological DMARDs for AA amyloidosis secondary to
RA
Tight control of RA during treatment is important for obtaining clinical remission or for low
disease activity [53]. This control is achieved via periodic assessments of RA disease activity
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and aggressive investigation of additional more effective treatments [54]. Biological
DMARDs (bDMARDs) therapy is expected to be effective against systemic inflammation and
local inflammation such as those occurring in RA.
Type of agent Biologic References
TNFα antagonist
IFX Arthritis Rheum 2002; 46: 2571
ETN/IFX Arthritis Rheum 2003; 48: 2019
ETN/IFX Rheumatology (Oxford) 2003; 42:1425
ETN Intern Med J 2004; 34: 570
ETN/IFX Rheumatology (Oxford) 2004; 43: 669
ETN/IFX Am J Med 2005; 118: 552
ETN Clin Exp Rheumatol 2007; 25: 518
IFX Rheumatol Int 2008; 28: 1155
ETN/IFX J Rheumatol 2009; 36: 2409
ETN Clin Rheumatol 2010; 29: 1395
ETN Rev Bras Reumatol 2010; 50: 205
ETN Rheumatol Int 2011; 31: 247
ETN/ADA Joint Bone Spine 2013; 80: 223
IL-6 receptor antagonist
TCZ Arthritis Rheum 2006; 54: 2997
TCZ Clin Rheumatol 2009; 28: 1113
TCZ Clin Rheumatol 2010; 29: 1195
TCZ Mod Rheumatol 2014; 24: 405
TCZ Amyloid 2015; 22:84
TCZ Clin Exp Rheumatol 2015; 33 (Suppl. 94): S46
Selective costimulation modulator of T-cell function
ABT Clin Exp Rheumatol 2014; 32: 501
Anti-CD20 antibody
RTX Joint Bone Spine 2011; 78: 98
DMARDs: disease-modifying antirheumatic drugs; AA: amyloid A; RA: rheumatoid arthritis; TNFα: tumor necrosis
factor α; IFX: infliximab; ETN: etanercept; ADA: adalimumab; IL-6: interleukin6; TCZ: tocilizumab; ABT: abatacept;
CD: cluster of differentiation; RTX: rituximab.
Table 2. Biological DMARDs for patients with AA amyloidosis secondary to RA.
Etanercept (ETN) and infliximab (IFX), both tumor necrosis factor α (TNFα) antagonists, can
lower SAA levels in RA patients with AA amyloidosis [55, 56]. This effect ameliorates both RA
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inflammation and AA amyloidosis, reduces the number of swollen and tender joints, lowers
or normalizes proteinuria, and improves renal function [57, 58]. Although a small number of
patients with AA amyloidosis secondary to RA received ETN, this drug had benefits for both
RA inflammation and AA amyloidosis, even in SAA1.3/1.3 allele-carrying RA patients (Table
2) [59–62]. Such benefits were determined by evaluating the surrogate markers disease activity
score 28-erythrocyte sedimentation rate, CRP, SAA, and proteinuria (Table 3). Also, patients
with mild RA disease and renal dysfunction demonstrated significantly improved serum
creatinine levels. This result suggests that an earlier intervention with bDMARDs produces a
better outcome for RA patients with AA amyloidosis (Table 4) [63, 64].
Parameter Initial visit Last visit P-value
DAS28-ESR 5.99 ± 0.69 2.99 ± 0.15 <0.01
CRP (mg/dl) 4.68 ± 0.87 0.48 ± 0.29 <0.01
SAA (μg/ml) 250 ± 129 26 ± 15 <0.01
Proteinuria (g/day) 2.24 ± 0.81 0.57 ± 0.41 <0.01
Creatinine (mg/dl)* 2.54 ± 1.38 2.50 ± 2.21 0.896
ETN: etanercept; AA: amyloid A; RA: rheumatoid arthritis; DAS: disease activity score; ESR: erythrocyte
sedimentation rate; CRP: C-reactive protein; SAA: serum amyloid A protein.
*Serum levels.
ETN was significantly effective for RA patients with AA amyloidosis. DAS28-ESR and CRP indicated RA
inflammation, and SAA and proteinuria-indicated AA amyloidosis. Quoted and modified from Nakamura et al. Clin
Rheumatol 2010; 29: 1395–1401.
Table 3. Effect of ETN on AA amyloidosis secondary to RA.
Creatinine value less than 2.0 (mg/dl) (n = 6) Creatinine value more than 2.0 (mg/dl) (n = 8)
Initial visit (mg/dl) Last visit (mg/dl) Initial visit (mg/dl) Last visit (mg/dl)
1.37 ± 0.49a 1.07 ± 0.59a 3.43 ± 1.14b 3.56 ± 2.39b
ETN: etanercept; AA: amyloid A; RA: rheumatoid arthritis.
Although a statistical significance of serum levels of creatinine was not observed as shown in Table 3, when cutting
levels of serum creatinine by 2.0 mg/dl, the group with values lower than 2.0 mg/dl revealed to be significant.
Regarding with renal dysfunction because of AA amyloidosis secondary to RA, the earlier the intervention, the better
the outcome was suggested. Quoted and modified from Nakamura et al. Clin Rheumatol 2010; 29: 1395–1401.
a P = 0.021, b not significant.
Table 4. Effect of ETN on renal dysfunction in AA amyloidosis secondary to RA.
Tocilizumab, an IL-6 receptor antagonist, also produced excellent SAA suppression and may
show promise as a therapeutic agent for AA amyloidosis [65–67]. Circulating SAA levels
usually indicate changes in CRP, and levels of these acute phase reactants usually increase at
the same time, but certain differences can occur. SAA and CRP seem to be somewhat affect‐
ed by different cytokines [68, 69]. As mentioned earlier, therapy in which IL-6 is blocked, rather
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than therapy utilizing TNF-α blockade, should influence multiple signal transduction systems
and may normalize SAA levels in RA patients (Figure 6) [70].
Figure 6. Changes in serum values of SAA between the first and last observations for each biologic. SAA values
showed more significant suppression in the tocilizumab group than in the TNF inhibitor group (P = 0.0194, Wilcoxon
rank sum test). Quoted and modified from Okuda et al. Mod Rheumatol 2014; 24: 137–143.
Figure 7. Clinical course of two RA patients with AA amyloidosis who received abatacept treatment. Clinical parame‐
ters were related to RA inflammation and AA amyloidosis after treatment. DAS28-CRP: disease activity score in 28
joints based on the CRP level; HAQ: Health Assessment Questionnaire; eGFR: estimated glomerular filtration rate; U-
protein: qualitative protein analysis of spot urine. Quoted and modified from Nakamura et al. Clin Exp Rheumatol
2014; 32: 501–508.
Abatacept (ABT) is a soluble fusion protein consisting of the extracellular domain of recombi‐
nant human cytotoxic T lymphocyte-associated antigen 4 plus a fragment of the Fc domain
human immunoglobulin IgG1 (CTLA-4Ig) [71]. CTLA-4Ig may reduce T lymphocyte respons‐
es by competing with CD80/CD86 to access CD28 and thus limit the CD28 signaling that T
lymphocyte activation requires [72]. ABT may also affect more than just T lymphocytes [73].
Whether intracellular signaling or other CTLA-4Ig-mediated effects contribute to a favorable
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outcome or a poor outcome, especially during the treatment of RA patients, is not entirely
clear, and the exact role of CTLA-4Ig in biological systems, including patients with AA
amyloidosis secondary to RA, is also unresolved. Although accumulating clinical data on ABT
treatment suggest an advantage for ABT in RA management [74, 75], the safety and efficacy
of ABT in patients with AA amyloidosis secondary to RA have not yet been studied. Figure
7 illustrates that in two patients, who had more than 20 years of RA history and who carried
the SAA1.3 allele, which is a risk factor for AA amyloidosis in Japanese RA patients, ABT
gradually improved RA disease activities, proteinuria, and various gastrointestinal symp‐
toms and was clinically effective to some degree in one case and completely in the other for
both RA inflammation and AA amyloidosis. Study results also suggest that ABT targeting of
costimulatory molecules may be useful for treating patients with AA amyloidosis secondary
to RA and that ABT may be an alternative to anti-cytokine therapies for AA amyloidosis
complicating RA [76].
Rituximab, an anti-CD20 monoclonal antibody, was effective for treating patients with severe
active RA who had an inadequate response to TNFα inhibitor (or inhibitors) [77]. The efficacy
and safety of rituximab for patients with AA amyloidosis secondary to RA together with
substantial clinical improvement in articular symptoms, marked reduction in acute phase
reactants, and stabilization of renal function and proteinuria were demonstrated [78].
5. Inhibiting AA amyloid fibrillogenesis in AA amyloidosis secondary to
RA
Highly sulfated glycosaminoglycans, especially heparan sulfate and dermatan sulfate
proteoglycans, are universal constituents of amyloid deposits and promote fibril assembly and
help maintain conformational changes related to amyloidogenesis [79, 80]. Eprodisate is a
negatively charged, sulfonated low molecular weight molecule that has a structure which is
similar to that of heparan sulfate [81]. It binds to the SAA binding site to prevent interaction
of SAA with glycosaminoglycans and thereby inhibits a conformational change required to
cause SAA to become amyloidogenic. In in vivo studies with murine models, eprodisate
inhibited the development of amyloid deposits [82, 83].
Eprodisate is still the only drug that was tested in a phase II/III multicenter, placebo-control‐
led, double-blinded study of amyloidosis [84]. Patients were stratified according to the
presence of nephrotic syndrome and the treatment center, after of which they were random‐
ized to receive eprodisate or placebo twice daily for up to 2 years. Outcome measures were a
composite endpoint of serum creatinine, creatinine clearance, and progression to end-stage
renal disease (ESRD) or death. Secondary outcome measures included the creatinine clear‐
ance slope, change in proteinuria, improvement in diarrhea, and alteration in amyloid content
of abdominal fat. The study demonstrated that eprodisate may have contributed to the failure
to achieve the study’s primary endpoints, although the eprodisate-treated group did show
renal benefits (Figure 8). The study, however, did not demonstrate a significant benefit from
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active therapy on progression to ESRD or risk of death, although a trend to benefit was seen.
A phase III clinical study is currently under way in Japan.
Figure 8. Kaplan-Meier survival curves for patients with AA amyloidosis who were given eprodisate or placebo. In
terms of event-free survival, eprodisate demonstrated superior effectiveness compared with placebo, but this effect
was not statistically significant. An event was defined as any component of the composite endpoint of worsened dis‐
ease. Quoted and modified from Dember et al. N Engl J Med 2007; 356: 2349–2360.
6. Immunotherapy for AA amyloidosis secondary to RA
An alternative therapeutic approach was to target other components of amyloid deposits to
destabilize amyloid fibrils. SAP is a normal plasma component and is a universal constitu‐
ent of amyloid deposits. Its presence may therefore mask the presence of amyloid deposits and
inhibit effective clearance of amyloid [85]. In fact, SAP knockout mice showed inhibited
amyloid formation [86]. SAP was identified as a therapeutic target, which then led to devel‐
opment of CPHPC, a drug that inhibits the binding of SAP to amyloid deposits [87]. The activity
of this agent relates to its ability to cross-link SAP molecule pairs face to face, which results in
rapid hepatic clearance and completely blocks the binding face of the SAP molecule [88]. A
preliminary study demonstrated that regular administration resulted in sustained and
profound SAP depletion. Several patients received the drug for many years with no obvious
adverse effects, although the degree of potential clinical benefit was not great enough to be
determined in this open, non-controlled study (Table 5) [89].
Antibodies recognizing a common fibril epitope were raised and given to mice [90] with
systemic AA amyloidosis, which resulted in reduced amyloid levels. CPHPC effectively
removed SAP from the blood, but only very slowly from amyloid deposits, which allowed the
development of an antibody directed at SAP. CPHPC was used to remove the SAP from plasma
followed by use of an anti-SAP antibody, which led to rapid clearance by macrophages of
experimentally induced amyloid deposits; this method begin developed for use in patients
[91].
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Patient no. Amyloid type Anti-SAP dose (mg) SAP scan Change in amyloid load
1 AA 5 Not improved None detected
2 AApoA1 637 Improved Liver reduction
3 AA 650 Improved Kidney reduction
AA: amyloid A; SAP: serum amyloid P component; CPHPC: (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-
hexanoyl]pyrrolidine-2-carboxylic acid; AApoA1: apolipoprotein A1.
Improved SAP scan: an improved scan was defined as a 123I-SAP scintigram revealing a reduction in organ amyloid
load at day 42 after SAP-antibody administration.
Combination treatment with CPHPC and anti-SAP antibody was effective to some extent for AA amyloidosis. Quoted
and modified from Richards et al. N Engl J Med 2015; 373: 1106–1114.
Table 5. Response of patients with AA amyloidosis to anti-SAP antibody after depletion of plasma SAP with CPHPC.
7. Biomarkers predicting effectiveness of treatment for AA amyloidosis
secondary to RA
Because renal dysfunction is the most common symptom in AA amyloidosis secondary to RA,
surrogate markers representing the effectiveness of each treatment were investigated, with a
focus on kidney function, in RA patients with AA amyloidosis who carried the SAA 1.3 allele
and who were treated with CYC or ETN focusing [92]. Identifying patients with a poor
prognosis when it may be possible to modify the disease process and in whom any therapy
may be justified is important. The presence of SAA1.3 allele in Japanese RA patients may be a
critical indicator for maintaining tight control of RA inflammation via vigorous treatment
during the early phase of the RA disease course [11]. The rationale for using biologics in AA
amyloidosis relates to their ability to lower levels of serum pro-inflammatory cytokines, which
regulate SAA synthesis [93, 94]. A retrospective study reported the efficacy and safety of ETN
for patients with AA amyloidosis secondary to RA who carried SAA1.3 allele [64]. Using ETN
for RA patients with AA amyloidosis may be possible, even for those undergoing dialysis [95,
96]. The efficacy of ETN was compared with that of CYC for treating AA amyloidosis
secondary to RA as related to the SAA1.3 allele, which was not a factor affecting therapeutic
susceptibility (Figure 9). Demonstrable endpoints included recovery of serum albumin
biosynthesis, improvement in the acute phase response, and amelioration of estimated
glomerular filtration rate (eGFR). SAA1.3 allele polymorphism was not affected on these
parameters (Table 6). Albumin in fact reflects the severity of AA amyloidosis [97]. The changes
in CRP and albumin were influenced by the difference between therapies rather than SAA1.3
allele polymorphism (Figure 10). In contrast, the eGFR in patients with end-stage renal damage
may reflect diminished urinary flow and may indicate improvement in renal function. Only
ETN aided the amelioration of the eGFR, which indicated the greater efficacy of ETN com‐
pared with CYC for treating AA amyloidosis secondary to RA.
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Figure 9. Kaplan-Meier survival curves after the treatment with ETN or CYC. ETN clearly demonstrated more effec‐
tiveness for RA patients with AA amyloidosis than did CYC. Quoted and modified from Nakamura et al. Rheumatolo‐
gy (Oxford) 2012; 51: 2064–2069.
Category CRP Alb eGFR Crea
Within-subject <0.01 <0.01 0.035 0.085
Interaction with
SAA1.3 allele polymorphism 0.777 0.715 0.465 0.228
Treatment (ETN/CYC) <0.01 <0.01 0.032 0.148
ETN: etanercept; CYC: cyclophosphamide; CRP: C-reactive protein; Alb: albumin; eGFR: estimated glomerular
filtration rate; Crea: creatinine.
Except creatinine, recovery of serum albumin biosynthesis, improvement in the acute phase response, and
amelioration of estimated glomerular filtration rate (eGFR) were valuable parameters to show effectiveness in the
treatment with etanercept. SAA1.3 allele polymorphism was not affected on these parameters. Quoted from Nakamura
et al. Rheumatology (Oxford) 2012; 51: 2064–2069.
Table 6. Parameters showing effectiveness of treatment with ETN or CYC.
Figure 10. Changes in the eGFR between initial and last visits according to the effectiveness of treatment with ETN or
CYC (A) and as a function of the SAA1.3 allele homozygosity or other polymorphisms (B). ETN increased the eGFR,
which improved the reduced renal function caused by AA amyloidosis, more than did CYC, and SAA1.3 did not affect
treatment in both groups of patients. Quoted from Nakamura et al. Rheumatology (Oxford) 2012; 51: 2064–2069.
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8. End-stage renal disease treatment in AA amyloidosis secondary to RA
Kidneys that have extensive AA amyloid deposits are extremely susceptible to intercurrent
insults such as hypoperfusion, hypertension, nephrotoxic drug effects, and surgical injuries,
which should all be avoided in AA amyloidosis [98, 99]. Renal involvement is the most
common problem in AA amyloidosis, and patients with AA amyloidosis frequently prog‐
ress to end-stage renal disease (ESRD) and poor prognosis (Figure 11). When evaluating
therapies for renal dysfunction related to AA amyloidosis, renal transplantation has been
thought to be a suitable method [100]. However, existing data on patient survival and graft
prognosis do not provide conclusive results about whether renal plantation is suitable for
patients with AA amyloidosis [101]. An alternative to transplantation is chronic dialysis, but
experience with dialysis in patients with AA amyloidosis has not yet as been encouraging [102,
103]. Peritoneal dialysis increases the susceptibility to infection and protein loss [104].
Hypoalbuminemia is well known to predict overall mortality in hemodialysis patients [105].
An elevated CRP value is associated with an increased risk of death in dialysis patients [106],
and CRP has been found to be an independent predictor of major adverse cardiac events [107].
Because patients with AA amyloidosis who have progressed to ESRD have already been
exposed to significant levels of inflammation, which may be ongoing, they may have an
additional cardiovascular risk [108]. Patients with marked proteinuria have an increased risk
of thrombosis, and the decision to use anticoagulants must be made on an individual basis
[109]. General management principles apply to patients with AA amyloidosis secondary to
RA for lowering high lipid levels and modifying diet as other causes of renal dysfunction.
Figure 11. Kaplan-Meier survival curves after diagnosis of AA amyloidosis for patients with serum creatinine values
of >2.5 or ≤2.5 mg/dl. Renal dysfunction, the most common symptom in AA amyloidosis secondary to RA, is a factor
indicating a poor prognosis for survival. Quoted from Nakamura et al. Rheumatology (Oxford) 2006; 45: 43–49.
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9. Possible involvement of phagocytes in degeneration of AA amyloid
fibrils
Macrophages participate in SAA processing and deposition [110, 111], and cell surface-
expressed heparan sulfate proteoglycans have an essential function in amyloidogenesis
through the binding of high-density lipoprotein-associated SAA [112]. In addition, Fc-
receptor-positive macrophages have been implicated in the reduction of the amyloid load after
inflammation has resolved [113]. Phagocytes such as neutrophils and macrophages will serve
an important function for reducing AA amyloid deposits during ABT treatment (Figure 12).
Figure 12. Immunohistochemical analysis of a biopsy specimen from a patient with RA and AA amyloidosis who re‐
ceived abatacept (ABT). (A) Stained with the antibody anti-formyl peptide receptor-like 1 (fPRL-1, the receptor in‐
volved in production of reactive oxygen species, degradation, and phagocyte migration) and (B) anti-human CD68
antibody staining. Phagocytes, polymorphonuclear leukocytes, and macrophages stained positively in the upper gas‐
trointestinal mucosa specimen. Quoted and modified from Nakamura et al. Clin Exp Rheumatol 2014; 32: 501–508.
Figure 13. Relation between macrophages and AA amyloid deposits. AA amyloid deposits showed positive Congo-red
staining (A), and anti-CD68 antibody-positive macrophages (arrows) surrounded AA amyloid deposits (B). These find‐
ings suggest an interaction between macrophages and amyloid deposits for the reduction in AA amyloid deposits.
Quoted and modified from Nakamura et al. Clin Exp Rheumatol 2014; 32: 501–508.
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T lymphocytes may influence the formation or metabolism of these amyloid fibrils. These cells
colocalized within AA amyloid deposits, which indicates that phagocytes may participate in
the metabolism or turnover of these amyloid deposits (Figure 13). Involvement of macro‐
phages in AA amyloid reduction was proposed [114], and this hypothesis was supported by
observations that macrophage-derived proteases completely degraded AA amyloid [115].
Resolution of AA amyloid deposits appears to start when inflammation subsides and SAA
levels normalize. Additional data on the natural clearance of AA amyloid are vital [116], for
both a better understanding of the dynamics of amyloidogenesis and the development of
effective treatments for patients with AA amyloidosis secondary to RA.
10. Conclusion
AA amyloidosis is an uncommon yet important complication of chronic inflammatory
conditions. Significant progress has been made in understanding of pathology, pathogenesis,
and clinical treatment of AA amyloidosis secondary to RA, but AA amyloidosis is still a serious
problem that deserves continued investigation. The SAA1.3 allele is both a risk factor for AA
amyloidosis and a factor related to poor prognosis and shortened survival in Japanese patients
with RA. The incidence of AA amyloidosis secondary to RA will likely decrease because of
remarkable advances in RA treatments such as bDMARDs and intracellular signal transduc‐
tion inhibitors. However, when rheumatologists first meet patients with AA amyloidosis
secondary to RA, the patients may be facing a serious, life-threatening disorder such as ESRD
and/or cardiac complications, even given the present medical milieu in developed countries.
The pathological process in RA patients with AA amyloidosis is likely to be more complicat‐
ed and subtle than previously realized. Clarification of the formation and degeneration of AA
amyloid fibrils induced by not only drugs but also cellular mechanisms and elucidation of the
biological significance of SAA in health and disease is indispensable prerequisites to the
management of AA amyloidosis secondary to RA. Novel therapies that target AA fibril
formation and immunotherapy are currently under investigation and will lead to improved
prognosis in the near future.
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